144 related articles for article (PubMed ID: 35605362)
1. Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies.
Wang X; Liu X; Huang J; Liu C; Li H; Wang C; Hong Q; Lei Y; Xia J; Yu Z; Dong R; Xu J; Tu Z; Duan C; Li S; Lu T; Tang W; Chen Y
Eur J Med Chem; 2022 Aug; 238():114461. PubMed ID: 35605362
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
[TBL] [Abstract][Full Text] [Related]
3. Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.
Wu T; Yu B; Gong W; Zhang J; Yu S; Tian Y; Zhao T; Li Z; Wang J; Bian J
Eur J Med Chem; 2023 Nov; 259():115711. PubMed ID: 37572539
[TBL] [Abstract][Full Text] [Related]
4. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Cidado J; Boiko S; Proia T; Ferguson D; Criscione SW; San Martin M; Pop-Damkov P; Su N; Roamio Franklin VN; Sekhar Reddy Chilamakuri C; D'Santos CS; Shao W; Saeh JC; Koch R; Weinstock DM; Zinda M; Fawell SE; Drew L
Clin Cancer Res; 2020 Feb; 26(4):922-934. PubMed ID: 31699827
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
7. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
9. The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.
Zhou F; Tang L; Le S; Ge M; Cicic D; Xie F; Ren J; Lan J; Lu Q
Oncotarget; 2023 Dec; 14():997-1008. PubMed ID: 38117531
[TBL] [Abstract][Full Text] [Related]
10. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
Freeman DB; Hopkins TD; Mikochik PJ; Vacca JP; Gao H; Naylor-Olsen A; Rudra S; Li H; Pop MS; Villagomez RA; Lee C; Li H; Zhou M; Saffran DC; Rioux N; Hood TR; Day MAL; McKeown MR; Lin CY; Bischofberger N; Trotter BW
J Med Chem; 2023 Dec; 66(23):15629-15647. PubMed ID: 37967851
[TBL] [Abstract][Full Text] [Related]
11. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
[TBL] [Abstract][Full Text] [Related]
13. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
[TBL] [Abstract][Full Text] [Related]
14. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
15. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
16. A patent review of selective CDK9 inhibitors in treating cancer.
Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J
Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
20. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
